Novo expects GLP-1 products to drive diabetes business growth

Drugs like Rybelsus and Ozempic are predicted to have the most impact on the growth of Novo Nordisk’s diabetes treatments, the company reveals on its capital markets day.
Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest | Photo: Novo Nordisk / PR
Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest | Photo: Novo Nordisk / PR
by marketwire, translated by catherine brett

Novo Nordisk now has a 30.3 percent share of the diabetes market, and is well on the way to achieving its long-term goal of controlling a third of the market. In 2019, the company’s market share was 28 percent.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading